Jazz Pharmaceuticals has delivered three consecutive earnings beats with large positive surprises and generates free cash flow that substantially exceeds reported net income — a hallmark of high-quality pharmaceutical cash economics — but the stock has reached near-term resistance with only 3.4% upside remaining, an unfavorable 0.6-to-1 risk/reward, an elevated put/call ratio of 2.1 signaling significant hedging activity, and high supply chain concentration risk identified in annual filings.
Thesis pillars
- Elevated Options Market Hedging↑Improving
- High Severity Supply Chain Concentration↑Improving
- Three Consecutive Earnings Beats→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis
Temporary headwind edge
Healthcare · Biotechnology
Wait for pullback to $197.41. Weak momentum; also recent C-suite change — blocks BUY_NOW at $205.06. Engine's entry $197.41 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: ESSDS; Earnings in 4 days (event risk).
Jazz Pharmaceuticals commercializes specialty medicines for rare diseases, with Xywav generating $1,657.0 million (41% of 2025 net product sales) for sleep disorders and Epidiolex generating $1,059.2 million (26%) for epilepsy. Rylaze, Zepzelca, Modeyso, and Ziihera round out... Read more
Wait for pullback to $197.41. Weak momentum; also recent C-suite change — blocks BUY_NOW at $205.06. Engine's entry $197.41 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: ESSDS; Earnings in 4 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Value play: 43% MoS with quality 8.2. Score 6.6/10, high confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news boost analyst 0.70, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 4d<=7d. Suitability: speculative.
About Jazz Pharmaceuticals plc
About Jazz Pharmaceuticals plc
Xywav generated $1,657.0 million in 2025 net product sales — 41% of Jazz Pharmaceuticals' total — making it the top revenue product, followed by Epidiolex at $1,059.2 million (26%), Rylaze at $402.9 million (10%), and Zepzelca at $307.3 million (8%). Jazz holds FDA approvals across six marketed products in narcolepsy, idiopathic hypersomnia, rare epilepsies, and rare oncology, and completed the $944.2 million Chimerix acquisition in April 2025, adding Modeyso (dordaviprone) for diffuse midline glioma under FDA accelerated approval in August 2025.
Jazz sells prescription medicines through specialty pharmacy channels. Xywav and Xyrem are distributed exclusively through ESSDS, a central certified pharmacy required by FDA under a REMS program with mandatory physician and patient enrollment before prescriptions can be filled. Epidiolex is reimbursed in more than 40 countries. Rylaze, the only recombinant erwinia asparaginase product on the U.S. market, is sold to cancer centers treating ALL and LBL. Zepzelca, licensed from PharmaMar, received FDA approval in October 2025 for first-line maintenance in extensive-stage SCLC in combination with atezolizumab, competing against Amgen's tarlatamab. Generic competition for the oxybate franchise is advancing: Hikma launched an authorized generic of high-sodium oxybate in January 2023, Amneal received FDA approval for its own generic in September 2025, and Ascent received approval in November 2025.
Show full overview
The oxybate franchise's durability turns on FDA-recognized orphan drug exclusivity for Xywav in narcolepsy through January 21, 2028 and in idiopathic hypersomnia through August 12, 2028. Lupin received tentative FDA approval for a generic Xywav in October 2023, and in January 2026 Tris Pharma filed a Section 505(b)(2) NDA for generic versions of both Xyrem and Xywav. Epidiolex faces authorized generic entry no earlier than the very late 2030s under settlements with ten ANDA filers. The company's ability to maintain oxybate revenues through these exclusivity windows while expanding Rylaze and Zepzelca constitutes the core near-term financial scenario.
See also: Healthcare · Biotechnology
From Jazz Pharmaceuticals plc's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-10-29Recent Developments — Jazz Pharmaceuticals plc
Latest news
- NEWS Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks - Yahoo Finance — Yahoo Finance positive
- NEWS Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks - finance.yahoo — finance.yahoo.com positive
- NEWS Nuvation, Jazz gain new Buys at Citi on oncology prospects - Seeking Alpha — Seeking Alpha positive
- NEWS Nuvation, Jazz gain new Buys at Citi on oncology prospects - seekingalpha.com — seekingalpha.com positive
- NEWS Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE) - Seeking Alpha — Seeking Alpha positive
Generated 2026-10-29T13:34:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductXywav41%10-K Item 1: 'net product sales of Xywav were $1,657.0 million, which represented 41% of our total net product sales for the year'
- MEDIUMProductEpidiolex26%10-K Item 1: 'Net product sales of Epidiolex/Epidyolex in 2025 were $1,059.2 million, which represented 26% of our total net product sales for the year'
- HIGHSupplierESSDS10-K Item 1A: 'We depend on outside vendors, including ESSDS, the central certified pharmacy, to distribute Xywav and Xyrem in the U.S.'
Material Events(8-K, last 90d)
- 2026-05-29Item 5.02LOWDirector Anne O'Riordan informed the Jazz Pharmaceuticals board she will not stand for re-election at the 2026 annual meeting of shareholders. No dispute or disagreement with company cited. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $197.41. Weak momentum; also recent C-suite change — blocks BUY_NOW at $205.06. Engine's entry $197.41 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: ESSDS; Earnings in 4 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Value play: 43% MoS with quality 8.2. Target $265.83 (+29.6%), stop $184.47 (−11.2%), A.R:R 4.7:1. Score 6.6/10, high confidence.
Take-profit target: $265.83 (+29.6% upside). Target $265.83 (+29.6%), stop $184.47 (−11.2%), A.R:R 4.7:1. Stop-loss: $184.47.
Concentration risk — Supplier: ESSDS; Earnings in 4 days (event risk); Negative momentum.
Jazz Pharmaceuticals plc trades at a P/E of 14.1 (forward 7.9). TrendMatrix value score: 8.3/10. Verdict: Buy (Wait for Entry).
28 analysts cover JAZZ with a consensus score of 4.2/5. Average price target: $295.
What does Jazz Pharmaceuticals plc do?Jazz Pharmaceuticals commercializes specialty medicines for rare diseases, with Xywav generating $1,657.0 million (41%...
Jazz Pharmaceuticals commercializes specialty medicines for rare diseases, with Xywav generating $1,657.0 million (41% of 2025 net product sales) for sleep disorders and Epidiolex generating $1,059.2 million (26%) for epilepsy. Rylaze, Zepzelca, Modeyso, and Ziihera round out the portfolio across rare oncology indications.